• Nicholas A Marston, Kevin S Shah, Christian Mueller, Sean-Xavier Neath, Robert H Christenson, James McCord, Richard M Nowak, Lori B Daniels, Judd E Hollander, Fred Apple, John Nagurney, Donald Schreiber, Christopher deFilippi, Deborah Diercks, Alexander Limkakeng, Inder S Anand, Alan H B Wu, Allan S Jaffe, W Frank Peacock, and Alan S Maisel.
• University of California, San Diego, California, USA.
• Emerg Med J. 2016 Jan 1; 33 (1): 23-9.

BackgroundCopeptin has demonstrated a role in early rule out for acute myocardial infarction (AMI) in combination with a negative troponin. However, management of patients with chest pain with a positive copeptin in the setting of a negative troponin is unclear.MethodsThe multicentre CHOPIN trial enrolled 2071 patients with acute chest pain. Of these, 476 subjects with an initial negative troponin but an elevated copeptin (>14 pmol/L) were included in this study. Copeptin and troponin levels were rechecked at 2 h and the final diagnosis of AMI was made by two independent, blinded cardiologists. Follow-up at 30 days was obtained for major adverse cardiac events (MACEs), including death, AMI and urgent revascularisation.ResultsOf the 476 patients analysed, 365 (76.7%) had a persistently elevated copeptin at 2 h and 111 patients (23.3%) had a copeptin that fell below the cut-off of 14 pmol/L. When the second copeptin was elevated there were 18 AMIs (4.9%) compared with 0 (0%) when the second copeptin was negative (p=0.017), yielding a negative predictive value of 100% (95% CI 96.7% to 100%). On 30-day follow-up there were 36 MACEs (9.9%) in the positive second copeptin group and 2 (1.8%) MACEs in the negative second copeptin group (p=0.006).ConclusionsPatients with chest pain with an initial negative troponin but positive copeptin are common and carry an intermediate risk of AMI. A second copeptin drawn 2 h after presentation may help risk stratify and potentially rule out AMI in this cohort.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

25 keywords...

hide…